Boston Scientific: Study to boost implantable cardiac devices market

07/21/2009 | Boston Globe (tiered subscription model), The

Boston Scientific believes that its MADIT-CRT study, which is aimed at testing the efficacy of cardiac resynchronization therapy in slowing the progression of early-stage heart failure, could expand the market for implantable heart devices. The company plans to ask the FDA to get expanded label indication for CRT defibrillators by the end of the year and hopes to secure approval by mid-2010, CEO Ray Elliott said.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA